Adderall XR News
Ahead of the Bell: Shire shares rise - MSN Money
Vyvanse is key to Shire's future, as its current top drug, Adderall XR, will lose patent protection next year. Shares of the British drug maker rose $2.85, ...
London shares close lower; weakness amon - Life Style Extra
The broker said that rapid growth of new product sales increases its confidence that the company can offset the loss of ADHD drug Adderall XR sales from May ...
ADRs in Focus: UK ADRs Gain Ground - Houston Chronicle
The company, which makes the attention deficit hyperactivity disorder drugs Vyvanse and Adderall XR, posted a profit of $1.11 per share, or 94 cents per ...
Shire's Vyvanse drug set to stay in spotlight - MarketWatch
Ramping up sales of Vyvanse and switching patients over to it from Adderall XR is crucial to Shire's future, because its older hyperactivity drug, ...
Market Report -- Short Stories (SHPGY) - MSN Money
EPS of $0.72 increased from their previous est of $0.70 due to strong TRx data for Adderall XR in Q4. SHPGY reported $0.41 in Q4, 2006, and the consensus ...
Shire's Vyvanse drug set to stay in spotlight - MarketWatch
all 4 news articles
Analysts are cautiously optimistic on Teva - Globes
In 2009, Citi expects Teva to launch generic Flomax, Topamax, Adderall XR, and Keppra. Citi sums up, "Increased revenue expectations for 2008 are offset by ...
ADRs in Focus: European Pharmaceuticals - Houston Chronicle
Shire also makes the older ADHD drug Adderall XR. The patents supporting Adderall expire next year, which will lead to competition from generic drugs, ...
Out of the Gate: Shire Stock Falls - Conde Nast Portfolio
Prescriptions of Vyvanse are growing slowly, Holford said, meaning Shire will lose customers when the patents on its older drug, Adderall XR, ...
Out of the Gate: Shire Stock Falls - Houston Chronicle
all 12 news articles
Adderall XR RSS Feed